# A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME)

> **NCT03666923** · PHASE1 · COMPLETED · sponsor: **ThromboGenics** · enrollment: 12 (actual)

## Conditions studied

- Diabetes Mellitus
- Diabetic Retinopathy
- Diabetic Macular Edema

## Interventions

- **DRUG:** THR-687 dose level 1
- **DRUG:** THR-687 dose level 2
- **DRUG:** THR-687 dose level 3

## Key facts

- **NCT ID:** NCT03666923
- **Lead sponsor:** ThromboGenics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-17
- **Primary completion:** 2019-11-20
- **Final completion:** 2019-11-20
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2020-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03666923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03666923, "A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME)". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT03666923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*